Why the study?
Does dabigatran etexilate improve stroke prevention and safety compared to VKAs in patients with non-valvular atrial fibrillation?
Does dabigatran etexilate improve stroke prevention and safety compared to VKAs in patients with non-valvular atrial fibrillation?
Effect estimate: RR 0.66
Absolute Event Rate: 1.11% vs 1.71%
p-value: p=<0.001
Dabigatran etexilate provides an effective and safe alternative to vitamin K antagonists for stroke prevention in non-valvular atrial fibrillation, without the need for routine laboratory monitoring.
No takes yet. Share an insight, caveat, or question.
Favors dabigatran over warfarin for stroke prevention in non-valvular AF; confirms randomized superiority and extends NOAC guideline recommendations.
Huber et al. (2013) conducted a review in Non-valvular atrial fibrillation (n=18,113). Dabigatran etexilate vs. Warfarin (target INR 2.0-3.0) was evaluated on Stroke or systemic embolism (RR 0.66, p=<0.001). Dabigatran etexilate 150 mg twice daily significantly reduced the risk of stroke or systemic embolism compared to warfarin (RR 0.66) in patients with non-valvular atrial fibrillation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: